Lacosamide ( DrugBank: Lacosamide )


4 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis3
46Malignant rheumatoid arthritis1
149Hemiconvulsion hemiplegia epilepsy syndrome2
298Hereditary pancreatitis1

2. Amyotrophic lateral sclerosis


Clinical trials : 645 Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03186040
(ClinicalTrials.gov)
July 13, 20175/6/2017Open-label Clinical Trial of Lacosamide in ALSOpen-label Clinical Trial: Safety of Lacosamide in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: LacosamideChiba UniversityNULLCompleted20 YearsN/AAll7Phase 1/Phase 2Japan
2JPRN-jRCTs031180173
07/07/201701/03/2019Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosisOpen-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis amyotrophic lateral sclerosis
amyotrophic lateral sclerosis;G122
gradual increase of lacosamide from 100mg to 400mg for 4 weeksKuwabara SatoshiNULLComplete>= 20age oldNot applicableBoth30Phase 1-2Japan
3JPRN-UMIN000027476
2017/06/0101/06/2017Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosisOpen-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis - Open-label clinical trial of lacosamide in ALS amyotrophic lateral sclerosisgradual increase of lacosamide from 100mg to 400mg for 4 weeksDepartment of Neurology Chiba University HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female30Not selectedJapan

46. Malignant rheumatoid arthritis


Clinical trials : 4,356 Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02342977
(ClinicalTrials.gov)
November 201418/12/2014Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.Osteoarthritis;Rheumatoid Arthritis;Avascular NecrosisDrug: Placebo;Drug: LacosamideIndiana University School of MedicineVA Office of Research and DevelopmentWithdrawn18 Years70 YearsBoth0Phase 2United States

149. Hemiconvulsion hemiplegia epilepsy syndrome


Clinical trials : 25 Drugs : 35 - (DrugBank : 13) / Drug target genes : 16 - Drug target pathways : 22
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-153104
18/3/201622/12/2015AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSYAN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY Epilepsy and epilepsy syndromeIntervention name : SPM927
INN of the intervention : Lacosamide
Dosage And administration of the intervention : oral administration
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.NULLcomplete4BOTH239Phase 3Japan, Asia except Japan, North America, Europe, Oceania
2JPRN-JapicCTI-153103
08/12/201522/12/2015A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSYA DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY Epilepsy and epilepsy syndromeIntervention name : SPM927
INN of the intervention : Lacosamide
Dosage And administration of the intervention : oral administration
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.NULLcomplete4BOTH242Phase 3Japan, Asia except Japan, North America, Europe, Oceania

298. Hereditary pancreatitis


Clinical trials : 95 Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05603702
(ClinicalTrials.gov)
November 202218/10/2022STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic PancreatitisSTTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic PancreatitisChronic Pain;Chronic Pain Syndrome;Chronic Pancreatitis;Hyperalgesia;Opioid Use Disorder;Opioid-Related Disorders;Opioid Dependence;Chronic Abdominal Pain;ERCP;Pancreatic SurgeryDrug: LacosamideIndiana UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruiting18 YearsN/AAll24Phase 1United States